Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000882104-20-000120
Filing Date
2020-08-07
Accepted
2020-08-07 20:33:52
Documents
99
Period of Report
2020-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q pdli-20200630.htm   iXBRL 10-Q 3315801
2 SHARE PURCHASE AGREEMENT pdli-2020063010qex101.htm EX-10.1 712102
3 CERTIFICATION pdli-2020063010qex311.htm EX-31.1 11107
4 CERTIFICATION pdli-2020063010qex312.htm EX-31.2 10661
5 CERTIFICATION pdli-2020063010qex321.htm EX-32.1 12083
11 LOGO pdli-20200630_g1.jpg GRAPHIC 123123
  Complete submission text file 0000882104-20-000120.txt   14922504

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT pdli-20200630.xsd EX-101.SCH 84884
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT pdli-20200630_cal.xml EX-101.CAL 104156
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT pdli-20200630_def.xml EX-101.DEF 663114
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT pdli-20200630_lab.xml EX-101.LAB 921355
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT pdli-20200630_pre.xml EX-101.PRE 781118
12 EXTRACTED XBRL INSTANCE DOCUMENT pdli-20200630_htm.xml XML 2679002
Mailing Address 932 SOUTHWOOD BLVD INCLINE VILLAGE NV 89451
Business Address 932 SOUTHWOOD BLVD INCLINE VILLAGE NV 89451 775-832-8500
PDL BIOPHARMA, INC. (Filer) CIK: 0000882104 (see all company filings)

EIN.: 943023969 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-19756 | Film No.: 201086536
SIC: 2836 Biological Products, (No Diagnostic Substances)